RedHill Biopharma (RDHL) Reports Q4 Operating Loss of $20.7M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts RDHL Hot Sheet
Join SI Premium – FREE
RedHill Biopharma (NASDAQ: RDHL) reported Q4 operating loss of $20.7 million. Revenue for the quarter came in at $22.1 million versus the consensus estimate of $24.08 million.
For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Kearny Financial (KRNY) Misses Q1 EPS by 2c
- Agnico, Barrick, and Newmont fall following broad Freedom Broker downgrades
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
